Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups

Courtney M. Rowan, Francis Pike, Kenneth R. Cooke, Robert Krance, Paul A. Carpenter, Christine Duncan, David A. Jacobsohn, Catherine M. Bollard, Conrad Russell Y. Cruz, Abhijeet Malatpure, Sherif S. Farag, Jamie Renbarger, Hao Liu, Giorgos Bakoyannis, Samir Hanash, Sophie Paczesny

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Assessment of prognostic biomarkers of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) in the pediatric age group is lacking. To address this need, we conducted a prospective cohort study with 415 patients at 6 centers: 170 were children age 10 years or younger and 245 were patients older than age 10 years (both children and adults were accrued from 2013 to 2018). The following 4 plasma biomarkers were assessed pre-HCT and at days17,114, and121 post-HCT: Stimulation-2 (ST2), tumor necrosis factor receptor 1 (TNFR1), regenerating islet-derived protein 3a (REG3a), and interleukin-6 (IL-6).We performed landmark analyses for NRM, dichotomizing the cohort at age 10 years or younger and using each biomarker median as a cutoff for high- and low-risk groups. Post-HCT biomarker analysis showed that ST2 (>26 ng/mL), TNFR1 (>3441 pg/mL), and REG3a (>25 ng/mL) are associated with NRMin children age 10 years or younger (ST2: Hazard ratio [HR], 9.13; 95% confidence interval [CI], 2.74-30.38; P = .0003; TNFR1: HR, 4.29; 95% CI, 1.48-12.48; P5 .0073; REG3a: HR, 7.28; 95% CI, 2.05-25.93; P =.0022); and in children and adults older than age 10 years (ST2: HR, 2.60; 95% CI, 1.15-5.86; P = .021; TNFR1: HR, 2.09; 95% CI, 0.96-4.58; P = .06; and REG3a: HR, 2.57; 95% CI, 1.19-5.55; P = .016). When pre-HCT biomarkers were included, only ST2 remained significant in both cohorts. After adjustment for significant covariates (race/ethnicity, malignant disease, graft, and graft-versus-host-disease prophylaxis), ST2 remained associated with NRM only in recipients age 10 years or younger (HR, 4.82; 95% CI, 1.89-14.66; P = .0056). Assays of ST2, TNFR1, and REG3a in the first 3 weeks after HCT have prognostic value for NRM in both children and adults. The presence of ST2 before HCT is a prognostic biomarker for NRM in children age 10 years or younger allowing for additional stratification.

Original languageEnglish (US)
Pages (from-to)1428-1437
Number of pages10
Issue number17
StatePublished - Apr 23 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups'. Together they form a unique fingerprint.

Cite this